ECNP Preclinical Network Data Prize Announced

We are happy to announce the winner of the ECNP Preclinical Network Data Prize. Based on the evaluation, the Prize was awarded to Laura Luyten and Tom Beckers(KU Leuven, Belgium) for the following paper.

Re-posted from ECNP

Luyten L, Beckers T (2017) A preregistered, direct replication attempt of the retrieval-extinction effect in cued fear conditioning in rats. Neurobiology of Learning and Memory 144: 208215. http://dx.doi.org/10.1016/j.nlm.2017.07.014

Special distinction
Since it was established in 2014, one of the core goals of the ECNP Network Preclinical Data Forum was to facilitate sharing of unpublished information between scientists (and particularly industry scientists where a lot of obstacles exist).

With this goal in mind, the Evaluation Committee has decided to award a Special Distinction to the paper written in collaboration by scientists from three pharma companies:

Latta-Mahieu M, Elmer B, Bretteville A, et al (2018) Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. Glia. 2018 Mar;66(3):492-504. http://dx.doi.org/10.1002/glia.23260

Evaluation process
Evaluation Committee has received a total of 30 nominations. Of these, sixteen met all eligibility criteria and each of them was subjected to an in-depth analysis. There were four to six reviewers invited to review each panel by answer sets of pre-formulated questions using a Likert scales. The questions were about the study design (blinding, randomization, sample size estimation, exclusion criteria), data analysis and statistics, quality of resources used and technical quality of a study in general, likelihood that these results are conclusive enough to prevent similar efforts, scientific strength and importance, and, last but certainly not the least, ethical aspects.

Due to a significant number of high-quality nominations, selection process was not easy and required an established of a dedicated data analysis panel composed of three renowned experts.

The ECNP Network Preclinical Data Forum is very grateful to all the colleagues who supported this project by acting as reviewers, experts and advisors!

Prevention of possible conflict of interest
Care was taken to ensure that handling of all nominations, the review process, the paper reviews themselves, communication with the reviewers and authors, and the decision-making related to the ranking of the nominations was done only by those without potential conflict of interest. Neither the sponsors of the Prize, nor the publishers represented on the Advisory Board were involved in this ranking.

The Network is planning to share more details about the process of evaluating publications with negative (null) results. Stay tuned!

Publication Award
The award itself will be a monetary prize of 10,000 (ten thousand) Euro, made available through a generous sponsorship support provided by the Cohen Veterans Bioscience. It will be awarded by the ECNP’s Preclinical Data Forum, which is a mixed industry and academic group which aims to improve the replicability and reliability of scientific data, especially in drug development. The winners are invited to attend an Award ceremony that will take place on Sunday, October 7, 2018 during the ECNP Congress in Barcelona. Travel and accommodation expenses will be covered by the ECNP, an Information Partner of the Award.

About the prize
What is believed to be the world’s first prize for published negative” scientific results, the ECNP Preclinical Network Data Prize” has been announced by the ECNP’s Preclinical Data Forum. The 10,000 prize, aimed initially at neuroscience research, is to encourage publication of data where the results do not confirm the expected outcome or original hypothesis.

“Negative” findings most often seen when researchers are unable to confirm or replicate previous results are often not submitted for publication. Studies with positive results are several times more likely to be published than those which do not result in a positive result. As a consequence, these data are effectively lost to science, which may lead other scientists to waste time and effort trying to duplicate literature results. A recent paper* estimated that this costs the US economy alone, $28bn each year, similar in scale to the total $35bn National Institute of Health annual budget**.

According to Dr Thomas Steckler (ECNP Preclinical Data Forum co-Chair, Janssen Pharmaceutica NV) “Science is historically self-correcting. This process is most effective when both positive and negative results are published. However, negative results are less likely to get published because they are often believed to generate less value” for an individual scientist, organization or journal. Indeed, compared with the positive data, negative data may appear less exciting, are less likely to open new avenues of research and therefore new funding opportunities. Unpublished data is effectively a waste of valuable real and human capital, particularly in the face of the reproducibility challenge currently discussed in various fields of science: reproducibility in neuroscience has come under particular focus in recent years. It’s startling to realize that over 50% of published biomedical data cannot be reproduced*”.

Dr Anton Bespalov (ECNP Preclinical Data Forum Co-Chair, PAASP), added “There are hundreds of drug trials which have failed in the last few years. Analysis of the factors that led to these failures is very often compromised by the biased representation of the early, preclinical work. The prize aims to emphasize to scientists and academic publishers that there is real value in publishing all the results, not just the headline-grabbing positive results”.

Read press release

References
*Kaiser, Science June 9th 2015. See http://www.sciencemag.org/news/2015/06/study-claims-28-billion-year-spent-irreproducible-biomedical-research** Science, July 17th, 2017 http://www.sciencemag.org/news/2017/07/house-bill-gives-nih-3-raise-blocks-cuts-overhead-payments

About the ECNP

ECNP is a scientific association dedicated to advancing the science of the brain, promoting better treatment and enhancing brain health. It is Europe’s leading independent forum for the science of CNS treatments. The ECNP Congress, Europe’s largest meeting on brain science, showcases the world’s best disease-oriented brain research, annually attracting between 4,000 and 6,000 neuroscientists, psychiatrists, neurologists and psychologists. ECNP’s wide range of scientific and educational activities, programmes and events make it the largest non-institutional supporter of applied and translational neuroscience research and education in Europe.

The ECNP Preclinical Data Forum, established by ECNP in 2014, was the founding basis, and now the European branch, of the Global Preclinical Data Forum.

More information about ECNP, it’s aims and activities, can be found here.

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/themes/cvb-theme/assets/img/icon-news-card.png

A Message from CEO Peter Hoehn

https://www.cohenveteransbioscience.org/wp-content/themes/cvb-theme/assets/img/icon-news-card.png

CVB President Nicole Harmon, PhD Discusses How Traumatic Brain Injury Has Impacted Her Family

https://www.cohenveteransbioscience.org/wp-content/uploads/2024/01/bibi-C-3.jpg

Interview with Bibi Carmouche, BASE Jumper for 22 Jumps Camelback Mountain 2024

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/03/cohen-veterans-bioscience-22-jumps.jpg

Cohen Veterans Bioscience and 22 Jumps Announce Parachuting with Purpose: Recognizing the Crisis of Veterans Suicide as a Result of Traumatic Brain Injury (TBI) and PTSD

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at media@cohenbio.org